Business development activities are gathering momentum and interest in Exopharm is building.
LEAP patent progressing to grant
The United States Patent and Trademark Office (USPTO) has upgraded the LEAP patent application (Application 17/147,033) to ‘Notice of Allowance Mailed’, indicating that the Examiner has accepted recent amendments to the Application, sees the Application as meeting its requirements and is ready to issue the requested patent (subject to some further steps and payment of fees).
Building financial value two ways
Exopharm is a leader in the exosome field. It is one of the few companies in the world with the capability to harness exosomes as a targeted delivery technology for therapeutic payloads such as gene therapy, RNA, small molecules and proteins.
Exopharm is developing its own exosome medicines as well as helping other companies use exosomes for their own pipelines and solve their drug-delivery problems.
Exopharm’s financial value will build in two ways: • in the value of exosome medicine products that we develop ourselves (our Pipeline Products); and • through multiple deals we do with partners and licensees (our Non-Dilutive Funding)
As one of a small number of companies with these capabilities, Exopharm is well-placed for partnership with pharmaceutical and biotechnology companies aspiring to use exosomes to deliver their assets inside the body.
EX1 Price at posting:
50.5¢ Sentiment: Buy Disclosure: Held
